Table 2. Clinical, immunological and adverse effects on vaccinated patients.
| Patient | DC (106)/ dose | Adjuvant | Adverse reactions | ELISPOT response | DTH KLH (mm) | DTH lysate (mm) | Stable disease (months) | Post-vaccination survival (months) |
|---|---|---|---|---|---|---|---|---|
| CT001 | 3–5 | KLH | Negative | + | + (6) | + (10) | 23 | 26 |
| CT002 | 3–5 | KLH | Fever | nt | − | − | − | 1 |
| CT003 | 3–5 | KLH | Negative | + | + (7) | + (7) | 20 | 21 |
| CT004 | 3–5 | KLH | Negative | − | + (7) | − | 18 | 21 |
| CT005 | 3–5 | KLH | Weak fever, knee inflammation. Anti-nuclear antibodies negative, rheumatoid factor negative | − | + (6) | − | 0 | 18 |
| CT006 | 3–5 | KLH | Negative | + | + (6) | + (9) | 22 | 24 |
| CT007 | 15–20 | KLH | Negative | + | + (10) | + (18) | 20 | 22 |
| CT008 | 15–20 | KLH | Negative | − | + (7) | − | 1 | 5 |
| CT009 | 15–20 | KLH | Negative | − | + (7) | + (10) | 21 | 22 |
| CT010 | 15–20 | KLH | Negative | + | + (8) | + (10) | 0 | > 16 |
| CT011 | 15–20 | KLH | Negative | + | + (6) | − | 0 | 7 |
| CT012 | 15–20 | KLH | Negative | − | + (6) | − | 0 | 11 |
| CT013 | 15–20 | KLH | Negative | + | − | + (7) | 17 | > 18 |
| CT014 | 15–20 | KLH + IL-2 | Weak fever | + | + (8) | − | 0 | 1 |
| CT015 | 15–20 | KLH + IL-2 | Weak fever, pain and reddening in inoculation site | + | + (6) | + (12) | 14 | > 15 |
| CT016 | 15–20 | KLH + IL-2 | Weak fever, pain and reddening in inoculation site | − | + (10) | + (45) | 15 | > 16 |
| CT017 | 15–20 | KLH + IL-2 | Weak fever, headache, flu-like symptoms | − | + (8) | + (8) | 13 | > 14 |
| CT018 | 15–20 | KLH + IL-2 | Weak fever, headache GII, flu-like symptoms GII | + | + (6) | + (6) | 0 | 6 |
| CT019 | 15–20 | KLH + IL-2 | Weak fever, headache GII | − | + (7) | − | 13 | > 14 |
| CT020 | 15–20 | KLH + IL-2 | Weak fever | − | + (8) | − | 0 | > 5 |
DC: dendritic cells; ELISPOT: enzyme-linked immunospot assay; DTH: delayed type hypersensitivity; KLH: keyhole limpet haemocyanin; IL: interleukin.